Overview
Stewart-Bluefarb syndrome (SBS), also known as acroangiodermatitis or pseudo-Kaposi sarcoma, is a rare angioproliferative disorder characterized by cutaneous manifestations resembling Kaposi sarcoma but associated with an underlying arteriovenous shunt 12.Diagnosis
Clinical Presentation: Lower leg pigmented macules, papules, and plaques that may coalesce into larger patches 1.
Differential Diagnosis: Often confused with Kaposi sarcoma, chronic venous insufficiency, and capillary malformations 1.
Histological Confirmation: Essential to differentiate from Kaposi sarcoma histologically 12.
Underlying Condition: Presence of an arteriovenous shunt should be identified 12.Management
Primary Treatment: Correction of the underlying arteriovenous shunt 12.
Supportive Measures: Compression devices for venous stasis 2.
Medications:
- Dapsone (dose not specified) 2
- Erythromycin (dose not specified) 2
Local Care: Topical steroids and wound care for ulcers 2.
Case-Specific Treatment: Heparan sulphate (Cacipliq20®) shown effective in treating chronic ulcers 2.Special Populations
No Specific Guidance: Abstracts do not provide detailed management insights for pregnancy, pediatrics, elderly, or specific comorbidities 12.Key Recommendations
Identify and Correct Underlying Arteriovenous Shunt: Essential for definitive management (Evidence: Moderate 12).
Histological Examination: Necessary to distinguish from Kaposi sarcoma (Evidence: Moderate 1).
Use of Heparan Sulphate for Ulcer Treatment: Consider in cases refractory to conventional treatments (Evidence: Weak 2).References
1 Parsi K, O'Connor AA, Bester L. Stewart-Bluefarb syndrome: Report of five cases and a review of literature. Phlebology 2015. link
2 Hayek S, Atiyeh B, Zgheib E. Stewart-Bluefarb syndrome: review of the literature and case report of chronic ulcer treatment with heparan sulphate (Cacipliq20®). International wound journal 2015. link